This document discusses several clinical studies on treatments for psoriasis and psoriatic arthritis. It outlines pros and cons of different assessment scales used to measure symptoms. It also summarizes key results from Phase 2 and 3 clinical trials of various biologic treatments for psoriasis and psoriatic arthritis, including guselkumab, risankizumab, and tildrakizumab. Finally, it notes the importance of assessing different symptom domains for psoriatic arthritis patients.
This document discusses several clinical studies on treatments for psoriasis and psoriatic arthritis. It outlines pros and cons of different assessment scales used to measure symptoms. It also summarizes key results from Phase 2 and 3 clinical trials of various biologic treatments for psoriasis and psoriatic arthritis, including guselkumab, risankizumab, and tildrakizumab. Finally, it notes the importance of assessing different symptom domains for psoriatic arthritis patients.
This document discusses several clinical studies on treatments for psoriasis and psoriatic arthritis. It outlines pros and cons of different assessment scales used to measure symptoms. It also summarizes key results from Phase 2 and 3 clinical trials of various biologic treatments for psoriasis and psoriatic arthritis, including guselkumab, risankizumab, and tildrakizumab. Finally, it notes the importance of assessing different symptom domains for psoriatic arthritis patients.
PROs: Psoriasis Symptoms and Signs Diary (PSSD) and
Psoriasis Symptom Scale Score (PSS)
Therapy Withdrawal in Psoriasis H2H Study Comparisons H2H Study Comparisons (cont) DISCOVER-1 and DISCOVER-2 Phase 3 Studies in PsA Guselkumab Key Results Risankizumab and Tildrakizumab Phase 2 Studies in PsA Importance of Different Domains in PsA Abbreviations